Cargando...
The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring
The expanded availability of adalimumab products continues to widen patient access and reduce costs with substantial benefit to healthcare systems. However, the long-term success of these medicines is highly dependent on maintaining consistency in quality, safety and efficacy while minimizing any ri...
Gardado en:
| Publicado en: | Front Immunol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8082443/ https://ncbi.nlm.nih.gov/pubmed/33936049 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.636420 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|